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Abstract
Atrial fibrillation (AFib) is a common cardiac arrhythmia associated with increased risk
for comorbid health conditions. Advancements in consumer technology have enabled
patients to monitor hearth rhythm independently, yet, much remains unknown about
patient outcomes related to the use of these smart device platforms (SDP). The aim of this
study was to examine the iatrogenic and/or remedial effects of SDP use on patient
reported outcomes of illness uncertainty, cardiac anxiety, body vigilance, AFib
symptoms, symptom burden, and healthcare utilization. The sample included 130 AFib
participants (65 in SDP group) recruited through ResearchMatch, American Heart
Association support forum, and other online AFib communities. Despite being of
younger age, participants in the SDP group reported more medical risk factors associated
with AFib. Results partially supported the iatrogenic effect, as participants with SDP
reported greater cardiac anxiety and healthcare utilization relative to those without, even
after accounting for covariates of age and medical risk factors. These findings should be
interpreted with caution, as the global pandemic may have impacted the results obtained.
Keywords: atrial fibrillation, smart device platforms, remote patient monitoring,
ECG, illness uncertainty, anxiety, healthcare utilization, Apple Watch, Kardia
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The Impact of Consumer Directed Remote Patient Monitoring Devices on Illness
Uncertainty and Anxiety in Patients with Atrial Fibrillation
Atrial fibrillation (AFib) is a heart condition characterized by disorganized
electrical signals that cause the cardiac atria and ventricles to desynchronize, resulting in
irregular heart rate. AFib is classified by duration and severity in five categories. First
diagnosed reflects the initial detection of AFib. Paroxysmal is the most common type of
AFib (January et al., 2014), marked by the sudden onset of arrhythmic episodes with
spontaneous recovery to sinus rhythm within seven days. Arrhythmias in persistent AFib
are sustained for seven days or more, whereas long-standing AFib reflects the
perpetuation of arrhythmic episodes for one year. Permanent AFib is assigned when no
further attempts to restore normal sinus rhythm will be made, though symptom
management may be warranted (Kirchhof et al., 2016).
At an estimated prevalence of 2.5% – 3.2% of the population (Chugh et al., 2014),
AFib is considered as the most common type of cardiac arrhythmia, affecting as many as
2.7 million Americans (Centers for Disease Control and Prevention, 2017) and 33.5
million individuals worldwide (Chugh et al., 2014). Approximately 1% of the population
is reported to have undiagnosed AFib (Jonas et al., 2018). Increasing age is a strong
predictor of AFib, with prevalence rates rising from <0.2% in adults younger than 55 to 8
– 9% in adults 65 and older, and 17.8% among those 85 and older (Go et al., 2001;
Heeringa et al., 2006). Owing to the growing aging population, the number of AFib
patients is expected to rise to 12 million Americans by 2050 (Lloyd-Jones et al., 2010).
The impact of AFib on physical health is significant, posing a great strain on
personal functioning and the healthcare system as a whole. AFib is a major cause of
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cardiomyopathy, heart failure, stroke, sudden death, and unexpected hospitalizations
(Miyasaka et al., 2007; Wolf et al., 1991). Moreover, the mortality rate of co-occurring
medical disorders is elevated by 200% (Kang et al., 2004). Increased risk of stroke has
been observed across permanent, persistent, and paroxysmal classifications of AFib (Link
et al., 2017). In fact, AFib confers a 5-fold risk of stroke (Stewart et al., 2002),
accounting for approximately 14 – 24% of ischemic stroke cases (Jonas et al., 2018).
Ischemic strokes secondary to AFib produce greater fatalities and disabilities relative to
those resulting from arterial disease (Lin et al., 1996). A CHA2-DS2-VASc score >2,
calculated based on history of congestive heart failure, hypertension, age, diabetes,
stroke, vascular disease, and sex, is typically used to estimate the probability for stroke
(Lip et al., 2010) and eligibility for anticoagulant therapy (Fitzmaurice et al., 2014). Age
is also strongly associated with thromboembolic events, with 1.5% increase of risk per
decade (Culebras et al., 2014). The cumulative health complications combined with rising
prevalence rates of AFib constitute a sizable financial burden on the healthcare system.
An annual estimate of seven billion dollars is directed towards AFib in the US alone
(Coyne et al., 2006). Hospital admissions for AFib total more than 1 million each year
(Tanigawa et al., 1991), reflecting a 66% increase in the past two decades (Friberg et al.,
2003).
AFib detection and treatment is complicated by the large proportion of patients
that do not present with symptoms. Approximately 40% of patients are asymptomatic or
have silent AFib (Granger et al., 2011). Patients who do experience symptoms often
report dizziness, palpitations, dyspnea, and chest discomfort in varying degrees of
frequency and severity (Kannel et al., 1998). Recurrence of both symptomatic and
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asymptomatic AFib is common within the same patient (Hindricks et al., 2005; Kirchhof
et al., 2009). Despite the dearth of symptoms experienced, silent AFib is as precarious, if
not more so, than symptomatic AFib. In a longitudinal community cohort study, 25% of
newly diagnosed residents were asymptomatic and were three times more likely to
experience an ischemic stroke prior to diagnosis (Miyasaka et al., 2007). Siontis and
colleagues (2016) found that asymptomatic AFib was associated with elevated risk for
cardiovascular and all-cause mortality relative to patients with typical AFib symptoms,
even after controlling for age and CHA2-DS2-VASc score.
Subclinical AFib is marked by the presence of atrial high rate episodes (AHRE)
that occur without corresponding symptoms. Patients with AHRE present with higher
rates of stroke when compared to the general population but lower rates compared to
patients with clinical AFib matched with similar CHA2-DS2-VASc scores (Healey et al.,
2012). The duration of AHRE associated with thromboembolic risk remains unclear.
Asymptomatic AHRE >5 minutes have been associated with a higher incidence of silent
ischemic brain lesions (Benezet-Mazuecos et al., 2014a), stroke, and systemic embolism
(Glotzer et al., 2003; Glotzer et al., 2009; Healey et al., 2012). The TRENDS (A
prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by
Implanted Device Diagnostics) study reported that AHRE totaling or exceeding 5.5 hours
a day doubled the risk for a thromboembolic event (Glotzer et al., 2009). ASSERT
(Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the
Atrial Fibrillation Reduction Atrial Pacing Trial) demonstrated a 2.5-fold increased
stroke risk among hypertensive patients with AHRE lasting longer than 6 minutes
(Healey et al., 2012), though a recent reanalysis of ASSERT showed that
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thromboembolic risks were only evident for episodes >24 hours. Additional research is
needed to quantify the duration of AHRE required to derive benefit from initiating
anticoagulation treatment in this subclinical population.
Uncertainty in AFib
The experience of patients in this disease population is laden with uncertainties.
Symptoms of AFib, such as fatigue, are often non-specific and occur intermittently,
posing a barrier to accurate and timely detection. As many AFib patients are older adults,
it is often difficult to determine whether symptoms are indicative of AFib or a normal
aging process (McCabe, Rhudy, Chamerlain, & DeVon, 2016). The risk status for cooccurring health conditions and all-cause mortality further complicates prognosis and
patients’ decisions regarding treatment options. Patients may face uncertainty in selecting
the optimal symptom management plan, as medications often have adverse side effect
profiles and are not recommended for long-term use (Fuster & Mearns, 2010).
Uncertainties, faced by both patients and caregivers, may also stem from deficient
knowledge or misunderstanding of the cause, meaning, and occurrence of AFib episodes,
as well as appropriate coping responses (Dalteg et al., 2014; Taylor et al., 2018).
Problematically, subjective reports of arrhythmias are often discrepant with
objective measures. The positive predictive value of AFib symptoms is estimated to
range between <10% and 52% (Atarashi et al., 2008; Barsky et al., 1994; Mehall et al.,
2007). Patients with a history of AFib may report arrhythmias during normal sinus
rhythm. False positive AFib episodes, or reported arrhythmias that occur during normal
sinus rhythm, account for 31 - 34 % of patient reports when compared to objective
measures obtained from electrocardiographic monitoring systems (ECG; Bhandari et al.,
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1992; Mehall et al., 2007). Furthermore, successful restoration of normal sinus rhythm
following treatment does not necessarily reduce subjective reports of AFib symptoms
(Fuster & Mearns, 2010). In a study following AFib patients who received ablation
treatment, one-third of participants reported symptoms that did not correspond to ECG
recordings (Björkenheim et al., 2016). Asymptomatic arrhythmias are also common
among patients who are nonresponsive to treatment. Among patients with a history of
paroxysmal AFib, asymptomatic episodes occurred 12.1 times more frequently than
symptomatic AFib, a ratio significantly higher than patients with supraventricular
tachycardia (Page, Wilkinson, Clair, McCarthy, Pritchett, 1994). In recent years,
advancing technologies have provided an avenue to resolve the uncertainties surrounding
the occurrence of arrhythmias.
Remote Patient Monitoring
AFib has typically been classified by the presence of cardiac arrhythmias (e.g.,
irregular R-R intervals coupled with the absence of identifiable P waves; January et al.,
2014) screened by 12-lead ECG in hospital or clinic settings, or continuous home ECG
devices, such as the 24-hour Holter monitor. These instruments, however, provide
relatively brief recordings that may not detect intermittent, asymptomatic, or subclinical
AFib. The development of long-term ECG monitors has enabled patients to document
AFib episodes that would typically have gone undetected.
Two of the most common continuous ECG systems are the implantable
cardioverter-defibrillator (ICD) and the implantable loop recorder (ILR). The ICD is an
implantable unit programmed to detect ventricular arrhythmias and deliver electrical
impulses to the heart to facilitate sinus rhythm (Magyar-Russell et al., 2011). Wireless
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features allow for data transmission to providers, which enable continuous monitoring of
patient vitals and ICD re-programing. The ILR is a single lead ECG monitoring device
that is also implanted subcutaneously. It detects AFib using algorithms that measure Rwave variability (Bumgarner et al., 2018). The clinical utility of these implantable
devices has been demonstrated in studies citing increased AFib-detection in stroke
patients relative to conventional strategies (Sanna, 2018) and prevention of fatalities
resulting from myocardial infarction (DiMarco, 2003). Despite the apparent benefits,
accessibility to these technologies is limited. The devices are only made available to
patients with known heart conditions. Moreover, the systems do not provide feedback to
patients, which may cause a degree of uncertainty and anxiety regarding equipment
reliability and patients’ health status (Skov et al., 2015).
Consumer Smart Device Platforms (SDP)
The latest innovations of heart monitoring systems are non-invasive and provide
continuous long-term ECG with interpretable results available to consumers on smart
device platforms (SDP). These consumer-directed devices record cardiac physiological
data supracutaneously in real time, typically using single-lead ECG technology, and alert
patients to arrhythmias corresponding to AFib. Data are stored in a web portal or mobile
application for patient self-monitoring and are transmissible to health care providers to
aid in guiding decisions regarding diagnosis and treatment. Public espousal of mobile
health care technologies has proliferated in the past decade. Sales of wrist worn smart
devices have grown exponentially, yielding a 20% growth between 2019 and 2020
(Strategy Analytics, 2020). Apple Inc. maintains the lead in the smartwatch market share,
with sales of 7.6 million units worldwide in the first quarter of 2020.
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Kardiaband was the first U.S. Food and Drug Administration (FDA) approved 1lead ECG Apple Watch accessory introduced in November 2017 (Husten, 2017). It was
made available to consumers for a price of $200. The Kardiaband replaces the Apple
Watch band and is compatible with series 1 – 3 Apple Watches. The SmartRhythm
system alerts patients to record an ECG when their heart rhythm deviates from the
predicted pattern (AliveCor, n.d.). Consumers can record their heart rhythm by placing
their thumb on the band’s sensor for 30 seconds. During ECG acquisition, the audio
recording feature on the Kardia app allows consumers to report co-occurring symptoms.
The Kardiaband algorithm interprets the ECG data, rendering five possible results:
Normal, Possible atrial fibrillation, Unclassified, Too short, and Unreadable. Data can be
transmitted to a cardiac technician for further assessment, with a one-hour response time,
for $9, or a board-certified cardiologist for a comprehensive clinical analysis, including
interpretation and recommendations, for $19, with results obtained within 24 hours. The
Kardiaband ECG algorithm was tested against physician-interpreted Kardiaband
recordings as well as 12-lead ECG recordings to measure its precision in detecting AFib
(Bumgarner et al., 2018). Of the interpretable results (66%), the Kardiaband algorithm
was determined to have 93% sensitivity and 84% specificity in distinguishing arrhythmia
from sinus rhythm in AFib patients. Sensitivity increased to 99% at a negligible cost to
specificity (83%) when Kardiaband ECG recordings were interpreted by physicians.
As a formidable contender in the consumer health technologies, Apple has
eliminated the need for the Kardiaband accessory by including a built-in ECG in recent
series of Apple Watches (series 4+). On September 12, 2018, Apple introduced the first
FDA-cleared commercially available ECG, making cardiac physiological data even more
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accessible to the general public (Apple, 2018a). During the Apple Special Event, the
Apple Watch series 4 received an endorsement from the president of the American Heart
Association, Dr. Ivor Benjamin, who described the ECG functionality as “game
changing,” with strong clinical implications in the “shared decision making between
people and their healthcare providers,” (Apple, 2018a). Similar to the SmartRhythm
function of the Kardiaband, the irregular rhythm notification feature of the Apple Watch
alerts individuals of arrhythmia and prompts for manual recording. ECG recording is
enabled by the placement of electrodes in the back and digital crown on the Apple Watch.
Consumers are directed to place their finger on the dial for 30 seconds to produce one of
three readings: No AF, Possible AF, and Unclassified. The FDA reviewed data from 588
Apple Watch users, approximately half of whom presented with permanent or persistent
AFib (Apple Inc., 2018b). Excluding unclassified recordings (10%), the AFib algorithm
demonstrated a sensitivity of 98.3% and specificity of 99.6%. Another study examined
the diagnostic sensitivity of the irregular rhythm notification feature against a continuous
ambulatory cardiac monitor and determined that 78.9% of irregular rhythm notifications
from the app corresponded with cardiac monitor detected AFib (Apple Inc., 2018b).
The application of consumer SDP in cardiac monitoring has received wide
acclaim for its promising diagnostic utility and undertaking to address issues with
discrepant symptom reporting in AFib. SDP are consumer friendly (i.e., easy to use) and
produce results in under one minute. They are affordable and non-invasive, thus,
minimizing costs, threats to infection, and physical discomforts commonly associated
with implantable devices (Lau et al., 2013). Clinically, consumer SDP may improve
diagnostic yield of silent and subclinical AFib, both of which confer a higher risk for
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stroke and other comorbid health conditions when compared to healthy samples (CITE).
A comparison study found that a smart-phone based ECG recording system outperformed
a standard cardiac event monitor in identifying arrhythmias and was better received by
patients, based on patient satisfaction measures (Macinnes et al., 2018). Early detection
of AFib may enable prompt initiation of treatment to attenuate disease progression
(Miyazawa et al., 2018). Moreover, the advent of these continuous mobile monitoring
systems may potentially resolve patients’ uncertainties about the occurrence of
arrhythmias. In spite of these possible gains, several unanswered questions remain with
interpreting SDP feedback, raising providers’ uncertainties for the optimal course of
treatment and patients’ uncertainties regarding the meaning of results.
The U.S. Preventive Services Task Force concluded that there is insufficient
evidence to evaluate the balance of benefit versus harm in screening for AFib with ECG
(Curry et al., 2018). The only known guidelines available, from the European Society of
Cardiology (ESC), European Heart Rhythm Association (EHRA), and AF-SCREEN,
recommend that patients with high risk-status for stroke, or those >75 years, be
considered for systematic ECG screening (Jonas et al., 2018). Among individuals 75
years and older, daily ECG recordings was reported to increase the detection of AFib
(Engdahl et al., 2013; Friberg et al., 2012; Kirchhof et al., 2009). Nevertheless,
recommendations on the screening frequency of the general population are lacking in the
literature. Furthermore, there are no known studies to date providing evidence that AFib
screening improves health outcomes.
The discussion of whether older adults benefit from remote technologies is mixed.
One study found no significant differences in activation and adherence to application-
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based remote monitoring of cardiac implantable electronic devices (CIEDs) across age
groups (Tarakji et al., 2018). Yet, a recent study examining ownership and utilization
preferences of health information technology noted that older adults (participants >65)
were less likely to own smartphones or tablets, and less likely to install health
applications (Onyeaka et al., 2021). The authors also found that older adults were less
likely to use technology to seek personal medical information, track healthcare costs,
communicate with providers, and view test results. When controlling for ownership of
smartphone, tablet, and internet use, these relationships remained significant, but were
attenuated, suggesting that age differences in health technology use was attributed to
technology access (Onyeaka et al., 2021). Other considerations in the adoption of health
technologies among older individuals may include interest, education, income, and health
status (Crouch & Gordon, 2019; Heart & Kalderon, 2013; Gordon & Hornbrook, 2018).
Thus, despite the higher rates of AFib among older adults as well as the potential benefits
of remote monitoring, older adults may experience unique barriers to using mobile health
technologies.
Uncertainties with SDP
Despite its FDA clearance, a diagnosis of AFib still requires physician
interpretation, as precision in SDP ECG falls short of gold standard. Approximately 15 –
33% of ECG recordings are determined to be “unclassified” by automated algorithms
(Bumgarner et al., 2018; Koshy et al., 2018). Passive identification of arrhythmias, such
as those measured by the irregular rhythm notification, poses a greater challenge to detect
in ambulatory populations relative to those at rest, as movement increases noise (Apple
Inc., 2018b; Tison et al., 2018). One study reported that the Apple Watch with
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Kardiaband rendered episode sensitivity of 97.5% in an ambulatory population compared
with an insertable cardiac monitor (Wasserlauf et al., 2019). In spite of this, Kardiaband
is no longer on the sales market. These uncertainties may prompt unnecessary worry in
patients, leading to additional testing to determine the possible presence of disease
(Mandrola, 2018; Sajeev et al., 2019; Wallace, 2019). Confirmatory tests are not without
risks. For instance, angiography is associated with a serious harm rate of 1.7% (Noto et
al., 1991). Moreover, repeated testing inflates the rate of Type I error, leading to a higher
incidence of false positives or misdiagnoses, as well as the potential for overtreatment.
The benefits of anticoagulant therapy in consumer SDP-detected AFib patients is
unknown (Sajeev et al., 2019; Sanna, 2018). The efficacy of oral anticoagulants in the
prevention of stroke has been demonstrated in patients diagnosed with AFib using
standard ECG equipment, which typically detect prolonged AFib episodes in paroxysmal
or persistent AFib patients (Sanna, 2018). In contrast, long-term remote monitoring
devices such as ICD, ILR, and consumer SDP passively detect all instances of AFib and
subclinical AFib. Patients screened with consumer SDP, such as the Apple Watch, may
differ in demographics and health status (i.e., younger, lower disease classification, lower
risk for stroke) relative to the “conventional AFib patient” diagnosed with standard ECG
(Mandrola, 2018; Sanna, 2018). Moreover, there is no consensus on the duration of
AHRE required to initiate treatment (Mahajan et al., 2018). Initiation of anticoagulant
therapy may be harmful, particularly for patients who are not at high risk for stroke, as it
has been associated with bleeding (Cameron et al., 2014).
Whereas the technical limitations of SDP will eventually be refined through
development, the clinical implications of their application remain understudied in this
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burgeoning field. Little is known about the psychological and behavioral impact of SDP
detected AFib, with regard to patient reported distress, healthcare utilization, disease
awareness, and symptom burden (i.e., symptom duration, severity, and frequency).
Patient reported outcomes offer valuable insight to the daily lives of patients and serve as
an important indicator of prognosis (Chan et al., 2009; Heidenreich et al., 2006;
Mommersteeg et al., 2009).
The widespread adoption of consumer SDP may generate a degree of worry and
uncertainty, as consumers may not be equipped with adequate knowledge about the
appropriate use of SDP, meaning of results, and optimal course of action (BenezetMazuecos et al., 2018). One randomized controlled trial (RCT) reported increased
anxiety among primary care patients systematically screened for AFib (Hobbs et al.,
2005). Irregular rhythm and ECG feedback from SDP may serve as a constant reminder
of the illness, enhancing anxiety, especially if results are interpreted without aid and
reassurance from medical providers (Ottenberg et al., 2013; van Hemel, 2009). Results
from a qualitative study highlighted a “vicious cycle” in AFib patients, whereby the
unpredictability of symptoms prompted ineffective coping strategies such as avoidance
and activity reduction (Taylor et al., 2018). Failed attempts to control symptoms elicited
increased distress, which in turn triggered or enhanced awareness of AFib symptoms.
Indeed, unpredictable events are reported to have a greater negative impact on mood,
anxiety, and physiological reactivity than aversive events that are expected (Grupe &
Nitschke, 2013; Sarinopoulos et al., 2009). Yet, the available research examining the
impact of continuous health monitoring on anxiety is equivocal.
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REHEARSE-AF is the only known RCT comparing the psychological outcomes
of one-lead ECG Kardia device with routine clinical care in screening patients without a
prior diagnosis of AFib (Halcox et al., 2017). Compared to treatment as usual,
participants in the SDP condition reported less anxiety about abnormal heart rhythm
results, despite increased awareness of risk. The results of this study should be interpreted
in light of several caveats. Participants in the SDP arm were only asked to measure their
heart rhythm twice weekly. Per study guidelines, all abnormal Kardia ECG traces
obtained were automatically transmitted for secondary analysis by a cardiologist (Halcox
et al., 2017). As such, the results of this study may not generalize to consumers with
continuous and passive monitoring devices or those that are not monitored by healthcare
providers.
Studies of other patient samples have examined the effect of continuous
monitoring on anxiety and patient distress. Research in maternal health indicates that
continuous monitoring of fetal heart rate using an ECG device is both feasible and
acceptable to pregnant women (Crawford et al., 2018). Anxiety was assessed before and
after monitoring using four validated questionnaires. No change in anxiety was observed
in three out of four measures, though significant score reductions were noted on the
Pregnancy Specific Anxiety scale. One meta-analysis highlighted the divergent effects of
continuous glucose monitoring (CGM) on patients with Type I diabetes (Messer et al.,
2018). Illness related distress was exacerbated with continuous monitoring, as the
constant feedback from the device seemed to overwhelm aspects of patients’ lives,
causing great anxiety (Barnard et al., 2014; Pickup et al., 2015; Rashotte et al., 2014).
Yet, another theme of the patient experience rested on the security, reassurance, and
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independence provided by the CGM devices (Pickup et al., 2015; Ritholz et al., 2014;
Wysocki et al., 2016). Continuous monitoring was reported to reduce fears of unexpected
hypoglycemia, allowing patients to resume daily activities.
The emotional burden of continuous heart rhythm monitoring with consumer SDP
is unknown. Relief and augmentation of AFib-related uncertainties are speculated as two
possible outcomes of constant physiological feedback. Continual monitoring of heart
rhythm in SDP obviates the need for patients to rely on subjective reporting of symptoms.
One qualitative study suggested that AFib patients with greater perceived knowledge
endorse greater feelings of control (Taylor et al., 2018). On the other hand, constant alerts
of heart rhythm abnormalities may enhance worry and potentially interrupt activities of
daily living, particularly if patients are uncertain about the meaning of results or the
appropriate course of action.
Healthcare utilization is another factor likely to be altered by the use of consumer
SDP. Stress-related hospital visits rise with increasing levels of uncertainty (Mishel et al.,
1984). Moreover, ECG screening has been linked to more downstream testing. Patients
who received an ECG during an annual medical exam were five times more likely to
receive additional cardiac tests, schedule subsequent visits, and obtain procedures than
those who were not screened (Bhatia et al., 2017). Continuous patient monitoring systems
may increase the need for additional tests among patients first diagnosed with AFib,
though alleviate the influx of clinic and hospital visits downstream, as data can be viewed
and monitored remotely (Dubner et al., 2012). Indeed, some studies have shown
significant reductions in health care utilization among cardiovascular (Brugada, 2006;
Burri & Senouf, 2009; Masella et al., 2008; Matlock, 2010), and COPD patients using
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remote patient monitoring systems (Dinesen et al., 2012). Other studies found no
differences in hospital admissions between patients using continuous monitoring devices
and those receiving conventional care (Ong et al., 2016; Pedone et al., 2013). A metaanalysis of RCTs examining health outcomes of heart failure patients found a significant
increase in unexpected hospital and emergency department visits in those with cardiac
implantable electronic devices (CIED; Klersy et al., 2016). Results from the
REHEARSE-AF study found that patients monitored by Kardia device reported that they
were less likely to schedule a follow-up visit with their physician for AFib-related
concerns relative to those receiving usual care. This study, however, assessed for
patients’ intended behaviors rather than actual behaviors (Halcox et al., 2017).
Plummeting rates of clinic admissions seem to be a plausible outcome of SDP use,
though patients may lose the opportunity to voice their concerns, receive reassurance, and
obtain important health information from providers (Pedersen et al., 2016; Simmers,
2012). The reduction of in-person contact with medical staff may induce anxiety in some
patients.
SDP use may subjectively or objectively alter the experience of patients’
symptoms by initiating changes in cognitive processes. High levels of uncertainty and
anxiety have been shown to enhance attention to pain and pain sensitivity (Ploghaus et
al., 2001; Sawamoto et al., 2000). In an experimental induction of uncertainty, threat of
shock amplified pain reactivity whereas expected shock exposures reduced physiological
indicators of arousal (Rhudy & Meagher, 2000). Another study found that participants in
the uncertain condition who received low intensity pain stimulation reported greater
perceptions of pain than subjects in the certain condition who received high intensity
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stimulation (Brown et al., 2008). Uncertainty has also been associated with perceived
pain elevations in patients with rheumatoid arthritis (Braden, 1990) and fibromyalgia
(Akkasilpa et al., 2000). Similarly, anxious individuals demonstrate biases in interpreting
ambiguous interoceptive stimuli as threatening (Richards et al., 2001) and attentional
biases in detecting the potential for impending harm (Bar-Haim et al., 2007; Beck &
Emery, 1985). For instance, patients diagnosed with panic disorder (PD) report greater
awareness of somatic sensations compared to those without PD (Chambless et al., 1984;
King et al., 1986), and demonstrate enhanced cardiac acuity relative to individuals with
infrequent panic episodes, simple phobias, non-anxious controls, and cardiac patients
(Ehlers & Breuer, 1992; 1996; Stalmann et al., 1987). AFib patients may be especially
motivated to detect symptoms of autonomic arousal that signify the possible presence of
an arrhythmic event, thereby increasing attunement to specific interoceptive sensations.
Heart-focused anxiety has been associated with greater vigilance for AFib symptoms as
well as increased pain frequency and intensity (Aikens et al., 2001; Fleet & Beitman,
1998; Zvolensky et al., 2003). This is further complicated by studies citing that
uncertainty and anxiety enhances heart rate variability (Gerstenfeld et al., 1999; Thayer et
al., 2012), which may mimic or exacerbate symptoms of AFib. Compared to nonanxious
individuals, patients with PD who perceived a cardiac event exhibited heart rate
accelerations (Pauli et al., 1991). It has yet to be determined whether consumer SDP
would amplify or attenuate patients’ AFib-related uncertainties and worries, thereby
altering attentional processes as well as patient perceptions of symptoms. Intuitively,
reliance on subjective pathophysiology is unnecessary when continuous objective
feedback of cardiac physiology is available, however, the immediate accessibility of
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health data may perpetuate symptom preoccupation, likening reception of ECG feedback
to a form of safety behavior. Indeed, one case study described the emergence of illness
anxiety disorder in an older adult female one year after diagnosis of paroxysmal AFib
(Rosman et al., 2020). The patient was found to have new onset health anxieties that were
primarily triggered by heart rhythm monitoring with a smart watch; Within a one-year
period, the patient had recorded 916 ECG tracings (701 in sinus rhythm, 55 possible AF).
The patient was reported to interpret ambiguous/inconclusive data as actual threats,
leading to numerous unnecessary clinic and emergency department visits.
In summary, although remote patient monitoring systems may answer questions
regarding the occurrence of cardiac arrhythmias, the psychosocial adjustment of patients
using SDP remains unknown. No study to date has examined the psychological sequela
of continuous, long-term, and passive heart rhythm monitoring in AFib. Yet, additional
research is needed to promote a greater understanding of patient reported outcomes in
order to develop comprehensive care for this population. The experience of uncertainty
among AFib patients using consumer SDP should be understood in the context of a
theoretical framework.
Mishel’s Midrange Theory of Uncertainty in Illness
Uncertainty is a strong predictor of psychosocial adaptation and disease outcomes
(McCormick, 2002). Given that uncertainty is a critical mark of the AFib patient
experience, the Uncertainty in Illness model (Mishel, 1988) provides a fitting theoretical
framework to guide the aims of this proposed study. The concept is defined as the
inability to derive meaning of illness-related events in the absence of sufficient
information (Mishel & Braden, 1988). Individuals living with uncertainty lack the
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cognitive framework to make sense of their diagnoses, symptoms, prognoses, and
treatments. Thus, they may perceive the disease to be unpredictable and uncontrollable
(Budner, 1962; Mishel, 1981; Weitz, 1989).
Mishel’s midrange theory of uncertainty in illness (1988) outlines three
components of the model: 1) antecedents, 2) appraisal, and 3) coping. The antecedents of
uncertainty include the stimulus frame, such as symptom patterns or event familiarity.
These illness-specific characteristics are influenced by patient factors (e.g., cognitive
capacities) as well as the resources available to the patient (e.g., social support,
education). The valence of uncertainty is considered neutral until otherwise appraised, as
either negative or positive (Mishel, 1990). Appraisals of danger arise when uncertainty
indicates the possibility of an adverse outcome such as the diagnosis of a disease,
whereas appraisals of opportunity occur when the outcome is evaluated as positive
(Mishel, 1990). Uncertainty may also be interpreted as an opportunity under extreme
cases, as is the case when a terminal prognosis is presumed and not knowing is preferable
to certain threat. Appraisals of uncertainty determine the actions employed to cope with
illness-related experiences (Mishel, 1988). In the context of danger, individuals may rely
on mobilizing strategies, such as information seeking or reframing, to increase the
perception of control and regulate affect (Afifi & Weiner, 2004; Mishel, 1990). In
contrast, opportunity appraisals require the persistence of uncertainty in order for positive
inferences to be maintained (Mishel, 1990). Under circumstances of prolonged illness
uncertainty, such as chronic illnesses, positive adaptations may also be achieved when
patients accept uncertainty to be an inherent feature of life (Mishel, 1990).
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Represented in the Mishel Uncertainty in Illness scale are four critical factors
encompassing illness uncertainty that are relevant to the literature of behavioral sciences.
These include ambiguity surrounding the state of disease, complexity concerning
treatment, insufficient data regarding prognosis and diagnosis, and unpredictability of the
course of illness. With complex diseases, healthcare providers may face clinical or
professional uncertainty, defined as challenges in determining diagnosis, prognosis, and
appropriate treatment for illnesses (McIntosh, 1974). Research has documented variations
in practice across providers prescribing treatments for the same condition under high
uncertainty (Jette & Jette, 1997). With regard to AFib, the use of consumer SDP
expectedly generate a degree of clinical uncertainty in determining risk status and
duration of AHRE required to initiate treatment (Benezet-Mazuecos et al., 2018; Mela,
2018; Sajeev et al., 2019; Sanna, 2018). AFib patients are likely to experience event and
temporal uncertainty. Event uncertainty is experienced when the occurrence of a diseaserelated event is unknown (Monat et al., 1972), such as the occurrence of an arrhythmia or
other AFib symptoms. In temporal uncertainty, the timeliness of an inevitable outcome is
unknown (Monat et al., 1972), such as when one will experience an AFib episode.
Results of an experimental paradigm indicated that event uncertainty was associated with
heightened arousal and vigilance, whereas temporal uncertainty predicted the use of
avoidance strategies (Monat et al., 1972). Continuous monitoring devices may alleviate
event and temporal uncertainties of arrhythmias, however, the occurrence and timing of
thromboembolic events remain unknown. The effect of SDP on illness uncertainty is an
understudied area, ergo, the coping strategies of consumers are yet to be determined.
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Uncertainty has been found to be a strong predictor of psychological distress in
patients with arthritis (Nyman & Lützen, 1999; Wiener, 1975), postpolio syndrome
(Mullins et al., 1995), and cancer (Neville, 1998). Yet, few studies have examined illness
uncertainty among AFib patients, and the bulk of the extant literature has been produced
by the same author. Higher rates of illness uncertainty have been documented in patients
with AFib than in those with breast cancer, myocardial infarction, and renal disease
(Kang, Daly, & Kim, 2004). Factors contributing to illness uncertainty in AFib patients
include lower educational attainment and social support, as well as greater perceived
illness severity (Kang et al., 2004). Uncertainty in AFib has been associated with greater
symptom severity and poorer mental health. Moreover, the relationship between illness
uncertainty and mental health was mediated by the appraisal of uncertainty as a danger
rather than an opportunity (Kang, 2005). Those who appraised uncertainty as danger are
also more likely to subscribe to an internal health locus of control, or belief that health
outcomes are determined by one’s behavior (Kang, 2009). Kang (2006) also found
differential effects of appraisal influenced by mood, whereby depression was positively
and negatively associated with danger and opportunity appraisal, respectively. There are
no known studies evaluating the impact of consumer SDP on illness uncertainty in AFib
patients. As we shift towards increasing reliance on tele-monitoring systems in modern
healthcare, it is ever more critical to enhance our understanding of the user experience in
order to develop appropriate interventions that address patient needs.
Current Study Rationale
Technological advancements have enabled continuous and remote detection of
irregular heart rhythms, thereby reducing event and temporal uncertainties of AFib
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(Apple Inc., 2018a; Benezet-Mazuecos et al., 2014; Bumgarner et al., 2018). The
application of this new technology has implications in primary prevention, as both
symptomatic and asymptomatic AFib confer higher risk for stroke (Glotzer et al., 2003;
Glotzer et al., 2009; Healey et al., 2012; Stewart et al., 2002). Although continuous
feedback may reduce uncertainties about whether and when an arrhythmia has occurred,
it does not allow patients to draw definitive conclusions about the meaning of these
events or the appropriate course of treatment (Benezet-Mazuecos et al., 2018; Mahajan et
al., 2018). With limited research in this burgeoning field, the psychological outcomes of
SDP consumers are yet to be determined. Specifically, it is unclear how SDP feedback
will impact patients’ illness uncertainty, cardiac anxiety, attention to bodily symptoms,
disease burden (i.e., symptom duration, frequency, and severity), and healthcare
utilization. The proposed study aimed to elucidate the psychological sequela of consumer
SDP engagement. Two possible outcomes have been hypothesized.
With growing support from reputable institutions (e.g., AHA), advocates of
consumer-directed healthcare are optimistic for SDP to remedy psychosocial concerns in
AFib patients. The current study hypothesized a remedial effect, which is based upon
evidence supporting that additional information regarding the predictability of symptoms
reduces uncertainty in illness (Mishel, 1988). Patients who have historically relied upon
their own subjective interpretations of symptoms to detect AFib events may obtain relief
from non-invasive monitoring systems that measure their cardiac physiology. Data can be
transmitted to providers for analysis and treatment recommendations, circumventing
practical limitations of healthcare access and reducing financial burdens associated with
frequent visits (Bumgarner et al. 2018; Dubner et al., 2012; Halcox et al., 2017). The
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functionality of such devices may increase symptom predictability as well as patients’
perceived control over the disease. Exposure has been shown to be an effective
behavioral intervention to reduce illness uncertainty (Abramowitz & Arch, 2014;
Carleton, 2012). SDP feedback may serve as a type of exposure, potentially correcting
erroneous assumptions regarding interoceptive cues, thus diminishing heart-focused
anxiety. Taken together, consumer SDP may obviate the need to attend to AFib
symptoms, which in turn, enable more accurate perceptions of symptom frequency and
severity.
In contrast, a number of skeptics have expressed reluctance to endorse consumer
SDP whole-heartedly, noting the possible iatrogenic outcomes (Curry et al., 2018;
Benezet-Mazuecos et al., 2018; Mandrola, 2018; Mela, 2018; Rosman, 2020; Sajeev et
al., 2019; Sanna, 2018; Wallace, 2019). In the proposed study, an iatrogenic effect was
also hypothesized, whereby feedback enhances the salience of existing illness-related
uncertainties of risk, management, and treatment. Continuous reminders of disease may
overwhelm various aspects of patients’ life (Skov et al., 2015). Opportunities to address
patient concerns and receive reassurance from direct contact with providers may be
missed with remote monitoring (Ottenberg et al., 2013; Skov et al., 2015; van Hemel,
2009). Moreover, persisting uncertainties regarding the imminence of AFib events may
lead to greater vigilance of symptoms (Rosman et al., 2020). Enhanced cardiac anxiety
may elicit safety behaviors, or efforts to prevent the occurrence of feared outcomes (e.g.,
AFib symptoms) and promote a greater sense of security (Helbig-Lang & Petermann,
2010; Olatunji et al., 2011; White & Barlow, 2002). In AFib patients, these may include
excessive cardiac monitoring, clinic visits, and increased contact with healthcare
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providers despite the absence of real threats. Previous studies have shown that anxiety
and symptom preoccupation have been positively associated with the reported frequency
and severity of AFib symptoms (Kang, 2006; Kupper et al., 2013; Ong et al., 2006).
Similarly, the iatrogenic hypothesis posits that cardiac anxiety and vigilance for AFib
symptoms would be associated with increased disease burden (i.e., symptom duration,
frequency, and severity).
Study Aims and Hypotheses
Aim 1
Explore demographics and identify risk profile of patients in the current sample as
well as covariates in subsequent analyses.
H1a. It was hypothesized that the majority (>50%) of the overall sample (across
both recruitment methods) would be of middle to higher socioeconomic status, as
measured by household income and educational attainment.
H1b. It was hypothesized that sex would be related to outcomes of illness
uncertainty, cardiac anxiety, symptom preoccupation, AFib symptoms, AFib
disease burden, and healthcare utilization.
H1c. It was hypothesized that age would be associated with illness uncertainty,
cardiac anxiety, symptom preoccupation, AFib symptoms, disease burden, and
healthcare utilization.
Aim 2
Apply Mishel’s Uncertainty in Illness model (1988) as a framework to determine
the psychosocial adjustment of AFib patients across two conditions: 1) consumer SDP
users 2) non-SDP users (control). Determine whether patient reported outcomes of illness
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uncertainty, cardiac anxiety, symptom preoccupation, AFib symptoms, disease burden,
and healthcare utilization across SDP users and non-users lend support for a remedial or
iatrogenic effect.
H2a: It was hypothesized that illness uncertainty (MUIS) would differ across
conditions.
H2b: It was hypothesized that cardiac anxiety (CAQ-Total, CAQ-Fear, CAQAvoidance, CAQ-Attention) would differ across conditions.
H2c: It was hypothesized that symptom preoccupation (BVS) would differ across
conditions.
H2d: It was hypothesized that AFib symptoms (AFSS-Symptoms) would differ
across conditions.
H2e: It was hypothesized that disease burden (AFSS-Burden) would differ across
conditions.
H2f: It was hypothesized that healthcare utilization (AFSS-HCU) would differ
across conditions.
Aim 3
Explore the mechanism underlying SDP engagement and psychological
functioning. Specifically, this study sought to examine whether uncertainty in illness
mediated the relationship between SDP use and five outcome variables: cardiac anxiety,
symptom preoccupation, AFib symptoms, disease burden, and healthcare utilization.
H3a: It was hypothesized that illness uncertainty would mediate the relationship
between SDP use and cardiac anxiety, such that SDP use would be associated
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with illness uncertainty, which in turn would diminish (remedial hypothesis) or
enhance (iatrogenic hypothesis) cardiac anxiety.
H3b: It was hypothesized that illness uncertainty would mediate the relationship
between SDP use and symptom preoccupation, such that SDP use would be
associated with illness uncertainty, which in turn would diminish (remedial
hypothesis) or enhance (iatrogenic hypothesis) symptom preoccupation.
H3c: It was hypothesized that illness uncertainty would mediate the relationship
between SDP use and disease burden, such that SDP use would be associated
illness uncertainty, which in turn would diminish (remedial hypothesis) or
enhance (iatrogenic hypothesis) disease burden.
H3d: It was hypothesized that illness uncertainty would mediate the relationship
between SDP use and AFib symptoms, such that SDP use would be associated
illness uncertainty, which in turn would diminish (remedial hypothesis) or
enhance (iatrogenic hypothesis) AFib symptoms.
H3e: It was hypothesized that illness uncertainty would mediate the relationship
between SDP use and healthcare utilization, such that SDP use would be
associated with diminished (remedial hypothesis) or enhanced (iatrogenic
hypothesis) illness uncertainty, which in turn would diminish (remedial
hypothesis) or enhance (iatrogenic hypothesis) healthcare utilization.
Methods
Participants
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Participants in the current study were recruited via web-based platforms,
including ResearchMatch, American Heart Association support group, and other online
AFib communities (i.e., Facebook).
ResearchMatch is a recruitment registry where individuals enlist to participate in
clinical research studies by providing health information, such as medical diagnoses.
They are then matched to researchers based on medical information provided.
Participants were also recruited through the web-based atrial fibrillation community
support groups. An advertisement, providing general information about the study,
eligibility criteria, and contact information of the principal investigator, was posted and
made public on these online forums.
Procedure
AFib patients with consumer smart devices (e.g., Kardiaband, Apple Watch series
4+) were placed in the SDP condition. AFib patients who did not own smart devices were
in the non-SDP group. Data collection were monitored to ensure that the number of
participants within each condition was fairly equal. Inclusion criteria remained consistent
across recruitment methods and condition, with the exception of participants in the SDP
condition, who were qualified by their use of consumer smart devices. Participants were
eligible to participate if they were at least 18 years of age, proficient in the English
language, and received a medical diagnosis of AFib. Though not explicitly specified, the
recruitment method and completion of measures also required that participants have
Internet access.
Eligible volunteers on ResearchMatch received an e-mail notification from the
web-based portal inviting them to participate in a study examining the psychological
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correlates of atrial fibrillation, led by a researcher at the University of Missouri – St.
Louis. Interested participants notified ResearchMatch of their willingness to participate,
at which point, the volunteer’s contact information was released to the principal
investigator. Participants who indicated interest received an e-mail containing a link to
the online survey hosted by Qualtrics.
Participants recruited through online community support groups responded to an
advertisement that included a description of the study, eligibility criteria, contact
information for the principal investigator, and a direct link to the survey.
The COVID-19 pandemic unexpectedly emerged during data collection of the
study. An amendment was submitted to include two additional measures in order to
assess the impact of the global health crisis on participants. Results will be described in
the exploratory analysis section.
This study was approved by the University of Missouri – St. Louis Institutional
Review Board. Subjects provided informed consent through the online portal before
participating. The consent also indicated that participants would be eligible to enroll in a
raffle drawing to receive one of ten available e-gift cards worth $25 if they completed at
least 80% of the survey items. Odds of winning are approximately one in 13.
Materials
Participants completed measures at a single time point. All surveys were
administered via an online platform. Subjects were able to access the study through a link
that was hosted by Qualtrics. See Appendix A for a compendium of study measures.
Demographics
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Demographic information was collected on patients’ age, sex, ethnicity, religious
affiliation, marital status, educational attainment, employment status, and annual
household income.
Medical Status
Participants were asked to report on their AFib status as well as other comorbid
medical conditions. AFib-related inquiries included duration of diagnosis, classification
of AFib, history of significant medical events (i.e., stroke, myocardial infarction),
treatment(s) received, and history of conditions that would indicate an elevated risk status
(i.e., diabetes, hypertension, and vascular disease). Patients unable to report on their
medical history, due to unwillingness or uncertainty, had the option to indicate, “I am not
sure” on any of the items.
Measures
SDP-Use. Participants in the SDP condition were asked to report on their
engagement with consumer smart devices. Specifically, subjects indicated the frequency
with which they received irregular heart rhythm or SmartRhythm notifications, selfinitiated ECG tracings, submitted data for further interpretation, and requested in-person
or virtual visits with a healthcare provider following feedback. A composite SDP-use
score was generated by totaling the aforementioned items.
Illness Uncertainty. The Mishel Uncertainty in Illness Scale – Community Form
(MUIS-C; Mishel, 1997) is a uni-dimensional scale based on the original Mishel
Uncertainty in Illness Scale (MUIS-A; Hallberg & Erlandsson, 1991). The original
instrument was intended for hospitalized or acutely ill adults, however, the MUIS-C was
modified for use with non-hospitalized and chronically ill adults living in the community.
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The MUIS-C contains 23 items rated on a 5-point Likert scale, ranging from 1 Strongly
Disagree to 5 Strongly Agree. Total scores ranged from 23 to 115. Items include, “My
symptoms continue to change unpredictably,” and “My treatment is too complex to figure
out.” The MUIS-C has demonstrated acceptable to excellent reliability, with scores
comparable to the original scale (Mishel & Epstein, 1997). The MUIS-C demonstrated
excellent reliability in the current sample, with a Cronbach’s alpha score of 0.90.
Cardiac Anxiety. The Cardiac Anxiety Questionnaire (CAQ; Eifert et al., 2000)
assesses fear of cardiac-related stimuli and sensations. Respondents are asked to rate the
degree to which they experience heart-related concerns on a scale from 0 Never to 4
Always on 18 items. The CAQ produces a total score and three subscale scores: (a) fear
of cardiovascular sensations, (b) avoidance of activities that may elicit symptoms, and (c)
attention to cardiac symptoms. Sample items for each subscale include, “If tests come out
normal, I still worry about my heart,” “I avoid exercise or other physical work,” and “I
pay attention to my heart beat.” The psychometric properties of the total scale and the
three subscales have been shown to be adequate with regard to internal consistency and
convergent and divergent validity (Eifert et al., 2000). Reliability scores for the current
study were α = 0.74 for the total CAQ measure, α = 0.82 for CAQ-fear, α = 0.92 for
CAQ-Avoidance, and α = 0.71 for CAQ-Attention.
Health Care Utilization, Disease Burden, and AFib symptoms. The Atrial
Fibrillation Symptom Severity (AFSS; Dorian et al., 2002; 2013) is a disease-specific
measure consisting of 19 items that assess AFib symptoms, healthcare utilization, and
disease burden. The AFib symptom subscale assesses the degree to which respondents
have been bothered by seven individual AFib symptoms (e.g., palpitations, shortness of
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breath, and chest pain). Response options range from 1 I have not had this symptom in the
past 4 weeks to 5 A great deal. Disease burden is derived from the sum of symptom
frequency, duration, and severity scores. Items on the healthcare utilization (HCU) scale
assess the frequency of AFib related emergency room visits, hospitalizations, and
specialist visits. The AFSS has demonstrated acceptable internal consistency for HCU, α
= 0.67 and good reliability for disease burden, α = 0.72 (Dorian et al., 2002)
Symptom Preoccupation. The Body Vigilance Scale (BVS; Schmidt et al., 1997)
is an 18-item self-report measure that assesses attentional focus to physiological
sensations. BVS items measure the degree of preoccupation, perceived sensitivity to
changes in bodily sensations, and duration of attention to sensations on an 11-point
Likert-type scale 0 Not at all like me to 10 Extremely like me. Respondents are also asked
to rate the extent of vigilance to 15 bodily sensations, such as numbness, tingling, and
upset stomach. The BVS has demonstrated good internal consistency, convergent, and
discriminant validity in previous studies (Olatunji et al., 2007; Schmidt et al., 1997).
Cronbach’s alpha in this study was in acceptable limits, α = 0.75.
COVID-19. The COVID-19 measure assessed qualitative data about whether the
pandemic impacted participant’s responses. It also inquired about changes in health
concerns and behaviors, patient’s COVID-19 status, and beliefs about the risks for
complications.
Impact of Events Scale – Revised. The IES-R (Weiss & Marmar, 1997) is a 22item scale that measures subjective distress following an adverse event. This scale
corresponds to the symptoms of posttraumatic stress disorder. Respondents were asked to
indicate the degree to which they were bothered by experiences related to the pandemic
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in the past seven days on a scale of 0 Not at all to 4 Extremely. Examples include, “Any
reminders brought back feelings about it.” The IES-R produces a total score (ranging 088) as well as subscales scores of avoidance, intrusions, and hyperarousal. Subscales
scores are obtained by calculating the mean of subscale items, with scores ranging from 0
to 4. Higher scores are indicative of greater pathology. A total score of 33 or more is
considered clinically significant. The IES-R has demonstrated good internal consistency,
test-retest reliability, and predictive validity in previous samples (Beck et al., 2008;
Creamer et al., 2003; Weiss & Marmar, 1997). Cronbach’s alpha in the current sample
was excellent for the total and subscale scores (IE-Total α = 0.97; IE-Intrusion α = 0.92;
IE-Avoidance α = 0.90; IE-Hypervigilance α = 0.92).
Results
Data Cleaning
A total of 819 participants electronically provided informed consent and
completed the screener items to indicate that they met the inclusion criteria to participate
in the study. Of these participants, only 180 completed at least 80% of the scale items
(excluding option text responses containing display logic), a minimum requirement of the
raffle entry. The minimum number of items to enter the raffle varied upon the condition
and time of completion. Those in the SDP condition were presented with an additional
questionnaire assessing their SDP-use. Following the COVID-19 pandemic, two
additional scales were included in the battery to assess the degree to which the
coronavirus may have impacted participants’ responses. Thus, the minimum number of
items per condition/time is listed as follows: 125 (SDP condition before pandemic), 151
(SDP condition after pandemic), 117 (Non-SDP before pandemic), 143 (Non-SDP after
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pandemic). A significant number of participants completed less than 80% of items (n =
639). Of note, several hundred entries (400+) were received on the same day, with close
time stamps, and near-identical response styles, suggesting the possibility of “bot”
responses. Data from the remaining 180 participants were more closely inspected for
signs of careless, unusual, or bot-based responses.
Considering the potential for low quality data with web-based data collection,
several authors have identified various methods of quality assurance (Buchanan &
Scofield, 2018; Mason & Suri, 2012; Stieger & Reips, 2010; Teitcher et al., 2015). One
potential method to assess respondent effort is to examine the completion time of a task
(Mason & Suri, 2012). Stieger and Reips (2010) developed a Javascript encoded
UserActionTracer alongside web-based surveys to screen low effort responses based on
various metrics. The authors found that the most common occurrence of low motivation
responses was completion of items at a rate faster than the average reading speed.
Trauzettel-Klosinski and Dietz (2012) identified that the average reading rate is 987 (SD
= 118) characters per minute. Readers in the 95th percentile, at two standard deviations
above the mean, read at a rate of 1,223 characters per minute. This method was
empirically tested for its ability to distinguish between participants assigned to
automated, low effort, and high effort conditions (Buchanan & Scofield, 2018). Results
indicated that low effort and automated submission times were significantly faster than
high effort data. There were four versions of the online survey in the current study: (1)
Non-SDP condition before COVID-19 (2) Non-SDP condition after COVID-19 (3) SDP
condition before COVID-19 (4) SDP condition after COVID-19. The character counts for
each version were divided by 1,223 to calculate the critical reading rate per minute, then
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multiplied by 60 to identify the critical reading rate per second for the fastest readers (95th
percentile). For example, the character count for those in the Non-SDP condition before
COVID-19 was 13,664. Average readers would complete this survey in approximately
831 seconds and the fastest readers would finish at around 670 seconds. Time completion
across the sample ranged from 750 to 7,218 seconds. The median completion time of
respondents was 1,132 seconds. On average, participants in the SDP condition completed
the questionnaire quicker (948 seconds) than those in the Non-SDP condition (1,564
seconds). Based on the reading rate criteria, 51 participants were identified as low
motivation or automated “bot” responses (one in SDP condition before COVID-19 and
50 in SDP condition after COVID-19), and were excluded from subsequent analyses. The
total sample was 130 participants, with 65 participants in each condition.
Preliminary Analyses
All analyses were conducted with SPSS Version 27. Data were screened for
missing values. Additionally, relevant assumptions of tests were examined, with
adjustments made, prior to proceeding with proposed analyses.
A missing value analysis was conducted to identify potential patterns for missing
data. Little MCAR’s test revealed non-significant results for MUIS (χ2(175) = 148.47, p
= 0.93), CAQ (χ2(114) = 97.31, p = 0.87), AFSS (χ2(103) = 124.80, p = 0.07), and BVS
(χ2(172) = 138.09, p = 0.97). Missing values analysis for SDP-use measure was only
completed for subjects in the SDP condition, and results were also non-significant, χ2(27)
= 37.23, p = 0.09. These findings indicate that data were missing completely at random.
Expectation maximization (EM) produced values for missing items from the same scale
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or subscale, which were imputed to minimize its effect on subsequent tests. Scale and
subscale scores were generated according to developer scoring instructions.
Assumptions of all relevant statistical tests were examined prior to hypothesis
testing. All study variables followed normal distribution as indicated by skewness and
kurtosis values falling between -1.0 and +1.0, with the exception of SDP-use scores,
which demonstrated a skewness of 0.02 and kurtosis of -1.18. Square root transformation
of the variable increased the kurtosis value to acceptable limits (Skewness = -0.41,
Kurtosis = -0.83). Descriptive statistics and zero order correlations for all variables are
reported in Tables 1 and 2. In preparation for ANCOVA, the interaction between
condition and covariates were examined in the univariate model. Results were nonsignificant, indicating homogeneity of regression. Collinearity diagnostic tests showed
that Tolerance and Variance Inflation Factors were within acceptable limits, revealing no
issues with multicollinearity. Visual inspection of scatterplots was used assess linearity.
Levene’s test revealed non-significant results, indicating equality of error variances.
Standardized Z-scores were saved on each of the nine continuous variables to
determine univariate outliers. Using a cutoff score of + 2.5 (Meyers, Gamst, & Guarino,
2013), a total of seven univariate outliers were identified. Specifically, two outliers were
identified on the BVS, three outliers on the AFSS-HCU subscale, one outlier on the
AFSS-Burden subscale, and one outlier on the CAQ-Attention subscale. After
consideration, these cases were retained as the purpose of this study is to conduct an
exploratory analysis in a novel area, of which population means have yet to be
determined. Analyses were examined with and without the inclusion of univariate outliers
with no changes in outcome.
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A priori Power Analyses
A set of power calculations were conducted to estimate the required sample size
for this study. In order to determine the adequate sample size needed, a power analysis
was conducted using G*Power 3.1 (Faul et al., 2014). The second aim of this study was
tested with ANCOVA. Parameters for a priori power analysis included Cohen’s f
conventions for a medium effect size of 0.25, p < 0.05, and power of 80%. Based on
these assumptions, the desired sample size was determined to be 128 participants. To
determine the sample size required for the third aim, a power analysis was performed for
multiple linear regression, using a medium effect size (f2 = .15) at 80% power and an
alpha of 0.05. Results indicated that the desired sample size for this test was 68
participants.
Descriptive statistics
Demographics
A total of 130 participants were included in the analyses, with 65 in the SDP
condition and 65 in the control condition. All demographic data are reported in Table 3.
Participants’ ages ranged between 21 and 90 years, with a mean age of 59.18 (SD =
17.18). Approximately 43% of sample was female, 57% was male, and no participants
identified as a sex other than male or female. A majority of the sample self-identified as
White/Caucasian (88%), with a subset of participants identifying as racial or ethnic
minorities, such as Black/African American (4%), Asian (3%), Latinx (1.5%), American
Indian/Alaska Native (1.5%), or Other (1.5%). With regard to marital status, most
participants reported being married (72%), with the remainder reporting single status
(18%), separated (>1%), divorced (7%), or widowed (3%).
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Three quarters of participants reported obtaining a college degree (8% Associates
degree; 46% Bachelor’s degree; 29% Post-graduate degree). Approximately 14%
completed some college or attended a vocational/trade school. A minority of subjects
reported obtaining a high school diploma or GED (4%). The sample was evenly split
between those retired (46%) and those employed (48%), in both part time (9%) and fulltime positions (39%). Approximately 2% of participants were on disability, with a small
subset of subjects in unpaid positions such as homemaker (2%), student (>1%), or
unemployed (>1%). Data on annual household income indicated that many of the
participants made over $75,000 (48%), 8% earned $60,001 - $75,000, 22% earned
$45,001 - $60,000, 10% earned $30,001 - $45,000, and 12% earned less than $30,000.
Over one-half the sample identified as Christian (31% Roman Catholic; 26% Protestant
Christian), 26% reported no religious affiliation, 6% identified as Jewish, >1% were
Muslim, and 9% selected ‘Other’ as their religious affiliation.
Medical History
All health information is reported in Table 4. The sample was diverse with regard
to their atrial fibrillation classification, with more than half reporting paroxysmal AFib
(56%), 27% with persistent AFib, 13% with permanent AFib, and 5% reporting unknown
status. Patients initially learned about their diagnosis through their cardiologist (41%),
primary care physician (22%), or remote monitoring device (13%). A subset of
participants reported learning about their diagnosis during a visit to the emergency
department or urgent care (14%). The median number of years since diagnosis was five
(22% diagnosed in the past year; 35% diagnosed in the past three years; 54% diagnosed
in the past 7 years). Approximately 40% of the sample reported living with atrial
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fibrillation for ten or more years. Disease classification was examined for differences
across age, race, and sex. Demographic variables were not found to be associated with
disease classification.
Patients were also assessed for medical comorbidities, significant health events,
and heart-related procedures. Overall, 79% of the sample reported at least one medical
comorbidity. Specifically, 58% reported hypertension, 45% reported hyperlipidemia,
43% reported obesity, and 25% reported diabetes. One-quarter of participants reported an
incidence of cerebrovascular accident/stroke (19%) or myocardial infarction (6%). More
than half of participants underwent surgery (55%), with 35% receiving balloon
angioplasty, 35% receiving cardiac catheterization, 19% receiving stent placement, and
12% receiving coronary artery bypass graft (CABG). Patients also underwent minimally
invasive procedures for implantable cardioverter defibrillator (ICD; 18%), and
implantable loop recorder (ILR; 18%). A composite medical risk score was calculated by
totaling the count of comorbidities (i.e., diabetes) and procedures (i.e., stent). Medical
risk was examined for differences across age, race, sex, and disease classification. A
significant relationship was observed with regard to age, r(104) = -.28, p < .01, and AFib
classification F(2, 103) = 10.48, p < .001, η2 = 0.17. Younger respondents reported a
greater number of medical risk factors. Moreover, medical risk was significantly higher
for patients with persistent (M = 4.60, SD = 3.04) and permanent AFib (M = 4.71, SD =
3.75) when compared to those with paroxysmal AFib (M = 2.23, SD = 2.09). Medical risk
did not differ between persistent and permanent AFib. No other demographics were
found to be associated with medical risk.
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Patients reported being fairly knowledgeable about their condition (95%; n =
124), though a minority of subjects indicated having insufficient understanding (5%; n =
5). Three quarters of participants reported being very reassured (77%; n = 91), 18% felt
moderately assured (n = 21), and 5% were not at all reassured by their doctor’s diagnosis
(n = 6). A majority of participants reported symptomatic atrial fibrillation (67 %; n = 87).
Of those who were symptomatic, 34% reported low interference with daily activities (n =
26), 31% reported moderate (n = 24), and 35% indicated high interference with daily
activities (n = 27).
SDP-Use
The type of heart-monitoring device and frequency of use were examined among
participants in the SDP condition (n = 65). Most patients reported using Kardia
device/band (46.2%) or Apple Watch (series 4+) products (52%). Less than one percent
of the sample reported using the heart monitoring program on a Fit Bit watch.
Participants were asked to report on the frequency that they were device-prompted to
record ECG traces (i.e., irregular heart rhythm or SmartRhythm notifications). Two-fifths
of participants indicated that they have never been prompted (40%), 20% reported being
prompted once or twice, 22% reported being prompted monthly, 11% were prompted
weekly, and 8% of participants were prompted several times a week. Participants were
also asked to report on the frequency at which they self-initiated ECG recordings to
screen for arrhythmia. Results indicate that nearly one quarter of participants recorded
ECG traces several times a week (26%), 23% recorded weekly, 26% recorded monthly,
and 20% have recorded once or twice in their lifetime. Approximately 5% of participants
have never used the ECG function of their smart device. ECG recordings typically
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produce one of three outputs. On average, participants reported receiving ‘Possible AF’
result 30% of time (SD = 24.04), ‘Normal’ ECG tracings 36% of the time (SD = 27.37),
and ‘Unclassified’ results 20% of the time (SD = 21.42).
Among participants who have used the ECG function on their smart devices, a
majority indicated that they trusted the results obtained (82%). After obtaining results,
85% of participants have transmitted the data to a cardiologist, physician, or cardiac
technician for further analysis. On average, participants transmitted ECG data 44% of the
time (SD = 35.72). Moreover, approximately 92% of participants reported scheduling a
visit with a provider at least once following recordings. Typically, participants scheduled
an in-person/virtual appointment 52% of the time after receiving feedback from their
smart device (SD = 36.10).
Demographic and Medical Differences between Groups. Data were analyzed
to determine whether there were significant differences in characteristics across
participants in the SDP and Non-SDP groups. As stated, there were an equal number of
participants in each group (N = 130). The groups did not differ with respect to sex,
ethnicity, income, or marital status. Significant differences were found with age, F(1,
104) = 64.39, p < .01, d = 1.60, education, χ2 = 14.79, p < .05, Ф = 0.32, employment
status, χ2 = 49.90, p < .001, Ф = 0.62, and religion, χ2 = 26.70, p < .001, Ф = 0.46 across
conditions. Specifically, participants in the SDP group were younger than those in the
Non-SDP group (MSDP = 48.40, SD = 16.40; MNon-SDP = 69.56, SD = 10.13). Relatedly,
those in the SDP condition had disproportionately higher number of participants
reporting full-time employment (n = 43, expected count = 25.5), whereas those in the
Non-SDP group had a greater proportion of participants who were retired (n = 46,
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expected count = 30). Participants in the SDP condition also had more participants with
Bachelor’s degrees (n = 38, expected count = 30), compared to those in the Non-SDP
group. Lastly, more subjects in the SDP group identified as Catholic (n = 32, expected
count = 19.8). In contrast, the Non-SDP condition had disproportionately more
participants who did not report any religious affiliation (n = 22, expected count = 17.1).
Data were analyzed to evaluate between group differences in medical morbidities,
significant health events, and heart-related surgeries. The groups did not differ with
respect to AFib classification, hypertension, obesity, hyperlipidemia, catheterization, or
incidence of stroke. Rather, significant differences were found with regard to diabetes, χ2
= 15.85, p < .001, Ф = 0.35, myocardial infarction, χ2 = 4.80, p < .05, Ф = 0.19, stent
placement, χ2 = 11.96, p < .01, Ф = 0.31, ICD, χ2 = 18.42, p < .001, Ф = 0.38, ILR, χ2 =
9.19, p < .01, Ф = 0.27, CABG, χ2 = 16.22, p < .001, Ф = 0.36, and balloon angioplasty,
χ2 = 14.48, p < .001, Ф = 0.34, across groups. Specifically, participants in the SDP
condition were more likely to endorse a medical history of diabetes (n = 26, expected
count = 16.3), myocardial infarction (n = 7, expected count = 4), stent placement (n = 20,
expected count = 12.4), ICD (n = 21, expected count = 11.7), ILR (n = 18, expected count
= 11.4), CABG (n = 15, expected count = 7.7), and angioplasty (n = 16, expected count =
8.7).
Analyses of Study Aims
Research Aim 1. Explore demographics and identify risk profile of patients in the
current sample as well as covariates in subsequent analyses.
Hypothesis 1a. It was hypothesized that the majority (>50%) of the overall
sample (across both recruitment methods) would be of middle to higher
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socioeconomic status, as measured by household income and educational
attainment. Descriptive statistics were used to analyze the first hypothesis of the study.
As expected, the sample was of middle to higher socioeconomic status, based upon
indices of household income and educational attainment. Specifically, 56% of the sample
reported an annual household income over $60,000, with 48% earning more than $75,000
per year. According to the United States Census Bureau, the median household income in
2019 was $68,703 (US Census Bureau, 2020). The sample was also fairly well educated.
Three quarters of participants reported obtaining a Bachelor’s degree or higher, with 29%
completing a post graduate degree.
Hypothesis 1b. It was hypothesized that sex would be related to outcomes of
illness uncertainty, cardiac anxiety, symptom preoccupation, AFib symptoms, AFib
disease burden, and healthcare utilization. Analyses of variance (ANOVA) were
completed to assess sex differences in illness uncertainty, AFib symptoms, symptom
burden, body vigilance, healthcare utilization, and cardiac anxiety. Contrary to
hypotheses, no sex differences were found with regard to MUIS, F(1, 128) = 0.07, p =
.79, AFSS-Symptoms, F(1, 128) = 0.35, p = .55, AFSS-Burden, F(1, 128) = 1.67, p =
0.20, BVS, F(1, 119) = 1.02, p = .32, or HCU, F(1, 128) = 1.84, p = .18. There were also
no sex differences in the total cardiac anxiety measure, F(1, 128) = 0.30, p = .59, or the
subscales of fear, F(1, 128) = 0.23, p = .63, avoidance, F(1, 128) = 2.36, p = .13, and
attention F(1, 128) = 0.34, p = .56.
Hypothesis 1c. It was hypothesized that age would be associated with illness
uncertainty, cardiac anxiety, symptom preoccupation, AFib symptoms, disease
burden, and healthcare utilization. Pearsons correlations were run to examine the

SMART DEVICE USE IN AFIB PATIENTS

46

relationships between age and illness uncertainty, AFib symptoms, symptom burden,
healthcare utilization, body vigilance, and cardiac anxiety. Age was positively associated
with MUIS, r(104) = .43, p < .001, indicating that older participants reported greater
illness uncertainty. Age was negatively associated to CAQ-Total, r(104) = -.56, p < .01,
CAQ-Fear, r(104) = -.56, p < .01, CAQ-Avoidance r(104) = -.42, p < .01, CAQAttention, r(104) = -.45, p < .01, AFSS-Symptoms, r(104) = -.43, p < .01, BVS, r(98) = .38, p < .01, and HCU, r(104) = -.37, p < .01. These results indicate that older
participants reported less cardiac anxiety, AFib symptoms, body vigilance, and healthcare
utilization. Age was not found to be significantly related to symptom burden.
Research Aim 2. Apply Mishel’s Uncertainty in Illness model (1988) as a framework to
determine the psychosocial adjustment of AFib patients across two conditions.
Determine whether patient reported outcomes of illness uncertainty, cardiac anxiety,
symptom preoccupation, AFib symptoms, disease burden, and healthcare utilization
across conditions lend support for a remedial or iatrogenic effect.
Hypothesis 2a. It was hypothesized that illness uncertainty (MUIS) would
differ across conditions. A one-way ANCOVA was run to examine differences in illness
uncertainty between participants with and without SDP, while controlling for age and
medical risk factors that were found to be unevenly distributed across groups in earlier
analyses. As indicated, a composite score of medical risk was derived from aggregating
the total count of medical comorbidities and procedures for each participant. Results did
not indicate a significant difference in illness uncertainty between groups after
accounting for covariates. Means and standard deviations for all variables are reported in
Table 5.
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Hypothesis 2b. It was hypothesized that cardiac anxiety (CAQ-Total, CAQFear, CAQ-Avoidance, CAQ-Attention) would differ across conditions. An
ANCOVA was conducted to assess for differences in cardiac anxiety and subscales
across conditions while controlling for covariates of age and medical risk factors. There
was a significant between group difference in CAQ-Total, F(1, 102) = 18.18, p < .001, η2
= 0.15, CAQ-Fear, F(1, 102) = 15.49, p < .001, η2 = 0.13, CAQ-Avoidance, F(1, 102) =
4.04, p < .05, η2 = 0.04, and CAQ-Attention, F(1, 102) = 13.24, p < .001, η2 = 0.12. As
seen in Figure 1, participants in the SDP group reported higher cardiac anxiety, cardiac
fear, cardiac avoidance, and attention to cardiac symptoms relative to those in the NonSDP group.
Hypothesis 2c. It was hypothesized that symptom preoccupation (BVS)
would differ across conditions. An ANCOVA was run to assess for differences in body
vigilance between groups while accounting for covariates of age and medical risk factors.
No difference in BVS was found between SDP users and non-users.
Hypothesis 2d. It was hypothesized that AFib symptoms (AFSS-Symptoms)
would differ across conditions. An ANCOVA was conducted to examine differences in
reported AFib symptoms across groups while controlling for covariates of age and
medical risk factors. Results did not indicate a significant difference in AFSS-Symptoms
between SDP users and non-users.
Hypothesis 2e. It was hypothesized that disease burden (AFSS-Burden)
would differ across conditions. An ANCOVA was run to examine differences in
symptom burden across conditions while controlling for covariates of age and medical
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risk factors. Results did not indicate a significant difference in AFSS-Burden between
SDP users and non-users.
Hypothesis 2f. It was hypothesized that healthcare utilization (AFSS-HCU)
would differ across conditions. An ANCOVA was run to examine differences in
healthcare utilization across conditions while accounting for covariates of age and
medical risk factors. A significant difference was found, F(1, 102) = 5.85, p < .05, η2 =
0.05, with participants in the SDP group reporting higher rates of HCU relative to those
in the Non-SDP group.
Research Aim 3. Explore the mechanism underlying SDP engagement and
psychological functioning. Examine whether uncertainty in illness mediated the
relationship between SDP use and five outcome variables.
Hypotheses 3a-e. It was hypothesized that illness uncertainty would mediate
the relationship between SDP use and five outcome variables: 3a) cardiac anxiety,
3b) symptom preoccupation, 3c) disease burden, 3d) AFib symptoms, 3e) healthcare
utilization. Mediation analyses were planned to explore the relationships between SDPuse, illness uncertainty, and eight psychological outcomes, using PROCESS macro. No
multivariate outliers were identified using Mahalanobis and Cook’s distance indicators.
As with previous analyses, age and medical risk factors were included as covariates in
each mediation model. Mediation analyses were not completed as the assumptions for
mediation were not met. Specifically, Path A, which examines the relationship between
SDP-use and MUIS was not significant, B = -0.13, SE = 0.26, 95% CI [-0.65, 0.40], β = 0.08, p = .62. There was no association between SDP engagement and illness uncertainty.
Exploratory Analyses
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To date, the outbreak of severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), otherwise known as coronavirus disease 2019 (COVID-19) has escalated to a
global health crisis. Although respiratory distress is the most common presenting
symptom, cardiac complications secondary to COVID-19 have also been documented in
patients with and without previous heart conditions (Babapoor-Farrokhran et al., 2020).
The risk of these complications is elevated in patients with underlying medical conditions
(i.e., cardiovascular conditions, hypertension, type 2 diabetes), many of which co-occur
with AFib (Centers for Disease Control and Prevention, 2021). Moreover, irregular heart
rhythm has been found to be a symptom in moderate to severe cases of COVID-19. In an
international sample of patients from Wuhan China, cardiac arrhythmias were present in
17% of those hospitalized and 44% of ICU admits with COVID-19 (Wang et al., 2020).
Thus, contraction of the coronavirus may exacerbate existing symptoms of AFib and
other cardiovascular conditions.
On March 2020, an amendment was submitted to IRB to include two additional
measures to examine the impact of COVID-19 on patient’s experiences (COVID-19 and
IES-R). A total of 72 subjects completed the extended battery, 55 of which were in the
SDP group. Only 58 participants completed the survey prior to COVID-19, of which 10
were in the SDP group. Given the uneven distribution of participants completing the
extended measures in each condition, there was not enough power to detect within group
response differences (i.e. SDP condition before and after COVID). Post-hoc analyses
were run to examine pre- and post- COVID-19 responses when collapsing across groups.
Comparison of Responses Before and After COVID-19
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Several independent t-tests were run to examine differences in mean MUIS,
AFSS, CAQ, and BVS scores before and after the emergence of COVID-19. Results
indicate that MUIS and AFSS-Burden scores did not differ before and after COVID-19.
A significant difference was found in CAQ-Total, t(128) = -5.16, p < .001, d = 0.91,
suggesting that subjects participating after the pandemic (M = 2.10, SD = 0.69) reported
higher rates of cardiac anxiety relative to those who completed the study prior to the
pandemic (M = 1.53, SD = 0.56). In examining this effect more closely, all three CAQ
subscales were elevated in post-COVID-19 participants (CAQ-Fear, t(128) = -5.02, p <
.001, Mpre = 1.54, SDpre = 0.57, Mpost = 2.12, SDpost = 0.74, d = 0.86; CAQ-Avoidance,
t(128) = -3.09, p < 0.01, Mpre = 1.38, SDpre = 0.88, Mpost = 1.89, SDpost = 0.98, d = 0.55;
CAQ-Attention, t(128) = -5.13, p < 0.01, Mpre = 1.65 SDpre = 0.71, Mpost = 2.29, SDpost =
0.71, d = 0.91). Based on a comparison of BVS scores, t(119) = -4.46, p < .001, d = 0.81,
results also indicated that post COVID-19 participants (M = 23. 45, SD = 7.64) reported
greater vigilance of general bodily symptoms compared to pre-COVID-19 participants
(M = 17.68, SD = 6.29). A significant difference was observed in AFSS-Symptoms,
t(127) = -3.33, p < .01, d = 0.57, with post-COVID-19 participants (M = 21.10, SD =
9.35) reporting greater AFib symptoms than pre-COVID-19 participants (M = 16.31, SD
= 7.01). A significant difference was also found with HCU, t(128) = -3.02, p < .01, d =
0.52. Participants who completed the study after COVID-19 reported higher rates of
health care utilization (M = 7.26, SD = 2.53) relative to those who completed the study
prior to COVID-19 (M = 6.07, SD = 1.98).
Qualitative data on the COVID-19 Measure
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A total of 71 participants completed the COVID-19 measure. Of these cases,
approximately 63% of respondents indicated that the pandemic did not impact their
responses to the survey, 27% affirmed that survey responses were impacted by COVID19, and 10% reported being unsure. A majority of respondents reported a fair amount of
exposure to COVID-19 news (92%), with subjects initiating consumption more than once
a day (25%), once a day (32%), and several times (27%) since learning about the
pandemic.
Participants were asked to indicate their COVID-19 status. Approximately 7% of
respondents reported contracting the virus (3% of active cases at the time of completion),
67% had never contracted the virus, and 25% were unsure (i.e., had not been tested or
were awaiting test results). Approximately 47% of participants reported minimal
concerns with contracting or re-contracting the virus, 30% endorsed moderate concerns,
and 24% indicated elevated concerns. Participants were also asked whether they knew of
someone who had tested positive for COVID-19. More than half of participants had
known someone who had contracted COVID-19 (56%), 40% denied knowing anyone
who has contracted the virus, and 4% were unsure. Known contacts included a family
member (8%), friend (19%), colleague (11%), or a distant party that the patient knew of
(7%).
Participants were generally concerned about the impact of COVID-19 on health,
with 62% reporting increased health related concerns and 38% endorsing minimal
concerns. When asked whether participants believed AFib placed them at an increased
risk for COVID-19 complications, 64% reported Yes, 21% indicated No, and the
remainder were uncertain. With regard to attention to physical symptoms, less than one-
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half reported no change (45%), 37% reported increased attention, and 18% reported
reduced attention to physical symptoms.
One third of the sample reported that their lifestyles were minimally impacted by
COVID-19 (32%), 32% reported that they were impacted A fair amount, and 35%
reported they were impacted A lot or A great deal. To get a better sense of how patients
may have been impacted by the coronavirus, participants were asked whether and how
they modified their behavior following COVID-19. Approximately 84% of subjects
indicated that they had modified their behavior to some extent. Specifically, participants
endorsed the following changes: 9% did not attend work/school, 35% minimized/avoided
social contact, 35% increased hand-washing, 35% avoided public places, 36% avoided
touching one’s face, 31% used disinfectants, 33% wore a face mask, 10% consumed
herbal supplements or vitamins, and 18% canceled or avoided travel.
Impact of Events Scale – Revised (IES-R)
A total of 44 participants completed the IES-R (M = 37, SD = 22.31). A majority
of participants reported elevated scores on the total impact of events scale. Specifically,
59% of subjects produced a score of 33 or greater, which is indicative of clinically
significant symptoms of distress. The IES-R also produced the following subscale mean
scores: IES-Intrusion M = 1.63, SD = 1.04; IES-Avoidance M = 1.78, SD = 0.99, IESHypervigilance M = 1.62, SD = 1.14.
Total IES-R and subscales scores were found to be correlated with COVID-19
status, t(42) = -5.90, p < .001, d = 1.78. Participants who had contracted COVID-19 or
were awaiting test results (M = 51.19, SD = 19.52) reported greater symptoms of distress
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relative to those who had not (M = 21.46, SD = 12.89). Known contraction in others did
not impact IES-R scores.
An unplanned ANOVA was also conducted to explore the relationship between
IES-R and patient’s reported change in attention to physical symptoms following
COVID-19. Results were found to be significant, F(2, 41) = 8.36, p < .01. Notably,
participants reporting less attention and more attention to physical symptoms following
COVID-19 endorsed clinically significant distress (IES-R Score > 33). Tukey post-hoc
analyses revealed that mean IES-Total scores for participants reporting less attention to
physical symptoms (M = 54.85, SD = 18.93) was significantly higher than IES-scores for
participants reporting no change (M = 24.87, SD = 22.65) and more attention to physical
symptoms (M = 35.76, SD = 15.44).
Discussion
With the advent of wearable heart monitoring devices, consumers are now gaining
greater access to their personal health information. Although patient autonomy is
generally regarded as a favorable outcome of modern technologies, the behavioral and
psychological sequelae of smart device platform (SDP) use has yet to be examined.
Proponents have argued that wearable heart monitoring devices affords consumers an
increased sense of control and assurances regarding the incidence of arrhythmias, which
may aid in early intervention and identification of arrhythmias that may otherwise have
gone undetected, such as silent AFib or AHRE. Continuous remote heart monitoring
systems may also provide feedback about the effectiveness of interventions, such as
catheter ablation. Despite these potential benefits, SDP have also garnered concern across
members of the scientific community (Mandrola, 2018; Rosman et al., 2020; Sajeev et
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al., 2019; Sanna, 2018; Wallace, 2019). For instance, uncertainties may persist with
regard to overall health risk and treatment options, particularly for patients who do not
represent the “typical” demographic of AFib patients. Continuous feedback may serve as
a constant reminder of one’s disease, increasing vigilance to threat cues (Barnard et al.,
2014; Pickup et al., 2015; Rashotte et al., 2014). Moreover, anxious consumers may
engage in safety behaviors such as frequent checking and unnecessary healthcare
utilization as a means mitigate concerns (Rosman et al., 2020). Ultimately, these actions
may serve to maintain the pathology of illness anxiety. This study utilized Mishel’s
Uncertainty in Illness as a theoretical framework to elucidate the outcomes of SDP use by
comparing illness uncertainty, cardiac anxiety, body vigilance, AFib symptoms, symptom
burden, and healthcare utilization across AFib patients with and without remote heart
monitoring technology.
Overall, the sample was of middle to higher socioeconomic status, as measured by
indices of income and educational attainment. The study design required subjects to
complete measures online, thereby excluding participants with limited access to a
computer, tablet, or reliable internet. The discussion of socioeconomic status would be
incomplete without mention of race and ethnicity. Previous research indicates racial
disparities across AFib, with greater rates of AFib across non-Latinx White individuals
compared to African Americans, Asian-Americans, and Latinx-Americans (Ferdinand &
Puckrein, 2015). Despite having a greater number of shared risk factors for stroke and
AFib, African Americans have a lower incidence of AFib and a two-fold higher risk for
stroke when compared to non-Latinx White individuals (Shen et al., 2010). This may be
attributed to a number of factors related to SES, including reduced health literacy, limited
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access to health services, and differential delivery of anticoagulant medication (Christian
et al., 2003; Gardwood et al., 2010; Meschia et al., 2010; Soliman et al., 2009).
Consistent with previous research, the current sample of AFib patients was
predominantly White.
Age was associated with illness uncertainty, cardiac anxiety, body vigilance, AFib
symptoms, and healthcare utilization. Specifically, older participants reported greater
illness uncertainty, and lower rates of cardiac anxiety, body vigilance, AFib symptoms,
and healthcare utilization. Previous research indicates that anxiety disorders are generally
less common in older adults (Wolitzky-Taylor et al., 2010), however, it was expected that
older adults would report greater AFib symptoms and HCU as age has been associated
with increasing incidence of AFib and other health complications (Go et al., 2001;
Heeringa et al., 2006). Interestingly, younger participants reported greater medical risk
factors (i.e., diabetes, heart attack, stent placement) relative to older participants in the
current sample. Considering this elevated risk profile, younger participants may report
greater cardiac concerns and attention to cardiac symptoms, which would increase AFib
symptom count and use of healthcare services. Relatedly, illness uncertainty was
inversely associated with medical risk. Individuals with high rates of comorbid medical
conditions may be more likely to receive additional care and testing, thereby increasing
contact with providers to better understand their chronic conditions and available
treatment options.
Participants in the SDP condition were younger and were more likely to hold fulltime employment. These findings are consistent with previous research indicating lower
ownership of smart devices among older adults (Carroll et al., 2017; Onyeaka et al.,
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2021). Despite being younger, participants in the SDP group reported greater risk profile
(i.e., diabetes, heart attack, stent placement, balloon angioplasty) than those in the NonSDP group. It is possible that health complications are emerging earlier in life and/or
being detected sooner. In young people (>50 years), AFib can be precipitated by
hypertension, hyperthyroidism, and heart disease as well lifestyle factors such as
exercise, alcohol, smoking, and diet (Chamberlain et al., 2011; Sankaranarayanan,
Kirkwood, Dibb, & Garratt, 2013). Obesity in children and young adults has risen
dramatically in recent decades, along with associated adverse health outcomes of
diabetes, hyperlipidemia, and cardiovascular disease (Centers for Disease Control and
Prevention, n.d.). Overconsumption of alcohol, a practice that is common in young
people, increases the risk of AFib by 37% (Djoussé et al., 2004). These findings illustrate
the trend of health complications emerging earlier in life due to poor lifestyle patterns.
An alternative interpretation of the study results is that younger participants with known
health problems may be more motivated to purchase SDP in attempts to monitor and
assume greater control of their overall health. Wearable smart devices may also alert
consumers to arrythmias that may otherwise have gone undetected, possibly identifying a
subset of younger AFib patients. Both age and medical risk were controlled for in
subsequent between-group comparisons.
Results partially supported the iatrogenic effect of wearable heart monitoring
technology, as evidenced by enhanced cardiac anxiety (fear, avoidance, attention) and
healthcare utilization in the SDP group, even after accounting for age and medical risk.
Participants in the SDP group reported increased fear, attention, and avoidance of
activities that elicit cardiac symptoms. Fear may interact with vigilance for cardiac
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symptoms in a positive feedback loop, whereby increased monitoring is employed to
mitigate health related concerns though has the unintended effect of enhancing
symptoms, thus increasing cause for concern. Despite increased cardiac attention, fear,
and avoidance in SDP users, there were no between group differences in body vigilance.
The BVS measured vigilance of general bodily symptoms which may not be specific
enough to capture attention to symptoms relevant for AFib patients. Interestingly,
participants in the SDP condition did not report any more AFib symptoms or symptom
burden than those in the control. Symptom inflation may be corrected by SDP, which
provides direct feedback about the incidence of arrhythmias. Symptom burden may also
be ameliorated by active attempts of SDP users to minimize AFib symptoms by avoiding
activities that would typically elicit cardiac symptoms. Avoidance may result from beliefs
about the risk of overexertion. Patients with smart devices will likely benefit from
additional information regarding the advantages of physical activity from providers and
explicit instruction of activities that are contraindicative for their conditions. Moreover,
the smart devices can increase engagement by setting specific activity goals for AFib
patients, based on provider recommendations, and providing feedback on progress.
Relatedly, consumers can set alerts on their watch to notify medication times, thus
increasing adherence.
Once consumers record ECG tracings, they are provided with opportunities to
engage with healthcare services. In the current sample, a majority of SDP users indicated
that they had transmitted data for further analysis at least once, and on average 44% of
the time. Moreover, after receiving ECG results, participants reported scheduling a
healthcare visit half the time. These results contrast those found in the REHEARSE-AF
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study, in which AFib patients monitored by Kardia devices reported that they were less
likely to schedule a follow up visit with a physician (Halcox et al., 2017). Notably, when
assessing patient’s actual rather than intended use of healthcare services, findings were
consistent with previous research indicating increased unexpected visits in AFib patients
with implantable devices (Klersy, et al, 2016). What remains unknown is the impact of
increased HCU. Do these additional visits/contacts ameliorate patient concerns more than
they otherwise would if patients did not receive feedback on remote heart monitoring
devices? To what extent does increased HCU benefit health outcomes of patients with
AFib? These are important considerations of future research.
Contrary to expectations, patients with SDP did not differ in illness uncertainty
relative to those without SDP. Moreover, SDP engagement was not associated with
illness uncertainty after accounting for age and medical risk factors. Though it is unclear
why these findings emerged, the relationship between SDP use and illness uncertainty
may not be as linear or clear-cut as it was originally conceptualized to be. For instance,
SDP may enhance illness uncertainty in a subset of users but diminish uncertainty for
others. Many individuals are prone to mobilize strategies such as information seeking to
reduce uncertainties (Afifi & Weiner, 2004). Although, individuals may also deliberately
avoid additional information in self-protection, if the state of uncertainty is preferred over
certain threat (Mishel, 1990). In this study, participants who endorsed diminished
attention to bodily symptoms following the pandemic also reported higher rates of
distress. Avoidance of stress-associated cues (i.e., bodily symptoms, COVID-19 news) is
a feature of post-traumatic stress (APA, 2013), and participants may be engaging in
avoidance as a way to manage their heightened distress. The current study did not
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identify potential moderating factors such as pre-existing anxieties and coping strategies
(i.e., monitoring and blunting), which may be an avenue of future research.
The results of this study should also be interpreted in light of a number of
limitations. First, the study design limits interpretations of causality. The use of heart
rhythm monitoring systems may promote or maintain cardiac anxiety, particularly in
individuals who are predisposed to anxiety. Indeed, one recent case study illustrated the
onset of illness anxiety in a newly diagnosed AFib patient (Rosman et al., 2020). Despite
sinus rhythm feedback from smartwatch and assurance from specialists, the patient
continued to exhibit heightened concern and perseverated on checking behaviors. The
patient excessively recorded ECG tracings and would even assume threat in innocuous
feedback results, leading to increased clinic visits and contact with providers (Rosman et
al., 2020). In contrast, it is also plausible that features on the smart devices are more
appealing to individuals with elevated cardiac anxiety. Due to the cross-sectional design
of the study, the direction of causality between cardiac anxiety and SDP use cannot be
determined, nor can it be assumed to be one-directional; Individuals with elevated cardiac
anxiety may be more inclined to purchase heart monitoring devices, and increasing use of
ECG may further enhance heart related concerns in a positive feedback loop. Future
research may explore this relationship more closely by examining the temporal sequence
of cardiac anxiety before and after SDP use in an experimental within-subjects paradigm.
Next, the online collection method confers a degree of risk for low quality data.
Conservative screening methods were used to address this issue post-hoc, though this
could have been better addressed by implementing a number of screening methods prior
to the collection process. Relatedly, the current study employed a relatively small sample
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size, which may limit the statistical power and increase the rate of Type II errors. Despite
this, the findings of the current study are an entrée to discussions of SDP patient
outcomes. Nevertheless, the literature would benefit from a replication of this study with
a larger sample size. Lastly, the results of the current study are complicated by the
emergence of the global pandemic, COVID-19. A majority of subjects who completed
the measures after the pandemic fell in the SDP group. Thus, it is difficult to ascertain
whether increased healthcare utilization is a function of SDP use alone, or resulted from
increased health-related concerns due to COVID-19, especially when considering that
SDP users reported more medical risk factors. Similarly, cardiac anxiety was found to be
higher in participants completing study measures after COVID-19, which may explain
significant group differences in CAQ total and subscale scores between the SDP and nonSDP groups.
Conclusion
This is the first known study to examine the psychological and behavioral
outcomes of consumer remote heart monitoring devices in AFib patients. This is an
important area of research given the espousal of SDP in an increasingly technologycentric world and acceleration of digital healthcare in modern medicine. Care should be
taken not to compromise quality for convenience, especially with the exponential growth
of telehealth services which has been an unexpected outcome of the current pandemic.
On one hand, telepsychology may enable patients to generalize and practice skills in
various domains (i.e., home, school, work). Moreover, patients living in rural areas will
have greater access to treatment. On the other hand, telehealth may be a disservice to
patients with agoraphobia, robbing them of opportunities to challenge the belief that
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home is the only “safe” space, and patients with body dysmorphia, who may turn off their
cameras for fear of offending others and would otherwise receive feedback that would
contradict these beliefs. To the extent that support and assurance ease distress, the
overuse of telepsychology may preclude patients from identifying alternative strategies to
manage difficult emotions, thus maintaining pathology. More information is necessary to
evaluate the costs and benefits of increased healthcare utilization in the context of cardiac
anxiety in AFib patients. Although the findings of this study are confounded by the
emergence of COVID-19, it remains that health complications are emerging earlier in
life, and with it, a population of younger adults in need of effective psychological and
medical care. As we look ahead to the future, it is incumbent on healthcare providers to
identify solutions and mobilize technologies responsibly to promote patient care.
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Table 1
Independent and Dependent Variable Descriptive Statistics
Measures

N

Mean

SD

Uncertainty in Illness

130

77.61

14.65

43.0

111.0

0.23

-0.66

Cardiac Anxiety Total

130

1.85

0.69

0.4

3.5

0.32

-0.34

Cardiac Fear

130

1.86

0.73

0.6

3.5

0.56

-0.44

Cardiac Avoidance

130

1.66

0.97

0.0

3.6

-0.03

-0.94

Cardiac Attention

130

2.01

0.78

0.0

3.6

-0.44

-0.04

121

20.88

7.60

2.3

45.4

0.29

0.51

AFib Symptoms

130

18.96

8.69

7.0

39.0

0.50

-0.61

Symptom Burden

130

17.09

5.33

3.0

30.0

-0.24

-0.16

Healthcare Utilization

130

6.73

2.37

3.0

15.0

0.87

0.59

65

3.66

1.04

1.4

5.2

-0.41

-0.83

Body Vigilance

Min

Max

Skewness Kurtosis

Atrial Fibrillation Severity Scale

SDP Use

Note. Uncertainty in Illness = MUIS Total Score; Cardiac Anxiety Total = CAQ Total
Score; Cardiac Fear = CAQ-Fear Score; Cardiac Avoidance = CAQ-Avoidance Score;
Cardiac Attention = CAQ-Attention Score; Body Vigilance = BVS Total score; Atrial
Fibrillation Severity Scale = AFSS; AFib Symptoms = AFSS Symptom Score; Symptom
Burden = AFSS Burden Score; Healthcare Utilization = AFSS HCU Score; SDP = Smart
Device Platform
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Table 2
Descriptive Statistics and Correlation Coefficients for Study Variables
Variable

1

2

3

1. BV

-

.099

-.205

-.035

2. HCU

.377**

-

.107

3. BURDEN

.340** .341**

4. AF SYMPTOM .377**

.267*

.364**

4

5

6

.305*

.159

.124

.054

.235

.009

-.051

.244*

.098

-.009

.167

.071

-.125

.568**

.371** .514**

.447**

-.583**

.736** .757**

.849**

-.490**

.283*

.464**

-.258*

-

.497**

-.425**

-

.243

.607**

6. CAQ-ATTN

.532**

.293*

.169

.377**

.723**

7. CAQ-AVOID

.391** .401**

.206

.611**

.809**

.336**

8. CAQ-FEAR

.483** .342**

.217

.488**

.918**

.625**

-.197

-.299*

-

-

-.637** -.498** -.303*

.581**

-

-.478** -.423**

Note. Correlations for control (non-SDP group) are presented above the dashes whereas
correlations for SDP group are presented below. Key: BV – Body Vigilance Scale; HCU
– Atrial Fibrillation Severity Scale Health Care Utilization; BURDEN – Atrial
Fibrillation Severity Scale Symptom Burden; CAQ-TOTAL – Cardiac Anxiety
Questionnaire Total Score; CAQ-ATTN – Cardiac Anxiety Questionnaire Attention
Score; CAQ-AVOID – Cardiac Anxiety Questionnaire Avoidance Score; CAQ-FEAR –
Cardiac Anxiety Questionnaire Fear Score; MUIS – Mishel’s Uncertainty in Illness Scale
Score
* p < 0.05; ** p < 0.01; (N = 130)

9

.570** -.021

.554** .421**

-.251

8

.365**

5. CAQ-TOTAL

9. MUIS

7

.003

-.458**
-

SMART DEVICE USE IN AFIB PATIENTS

94

Table 3
Demographic Descriptive Statistics by Condition

Demographics

Control (n = 65)

SDP group (n = 65)

n (%)

n (%)

Female

28 (43.1)

28 (43.1)

Male

37 (56.9)

37 (56.9)

1 (1.5)

1 (1.5)

-

4 (6.2)

1 (1.5)

4 (6.2)

61 (93.8)

54 (83.1)

Latinx

-

2 (3.1)

Other

2 (3.1)

-

2 (3.1)

3 (4.6)

11 (16.9)

4 (7.7)

-

2 (3.1)

Associates Degree

8 (12.3)

2 (3.1)

Bachelor’s Degree

22 (33.8)

38 (58.5)

Graduate Degree

22 (33.8)

15 (23.1)

1 (1.5)

2 (3.3)

Sex

Race
American Indian/Alaska
Native
Asian/Asian American
Black/African American
White (non-Latinx)

Education
Less than high school
High school or GED
Vocational/Trade school

Income
Less than $15,000
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$15,001 - $30,000
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4 (6.2)

8 (13.1)

Control (n = 65)

SDP group (n = 65)

n (%)

n (%)

$30,001 - $45,000

10 (15.4)

3 (4.9)

$45,001 - $60,000

10 (15.4)

18 (29.5)

$60,001 - $75,000

6 (9.2)

4 (6.6)

34 (52.3)

26 (42.6)

Full-time

8 (12.3)

43 (66.2)

Part-time

4 (6.2)

7 (10.8)

Home-maker

3 (4.6)

-

Unemployed

1 (1.5)

-

Disability

3 (4.6)

-

Retired

46 (70.8)

14 (21.5)

Student

-

1 (1.5)

Never married/Single

10 (15.4)

13 (20)

Married

45 (69.2)

48 (73.8)

Divorced

7 (10.8)

2 (3.1)

Separated

-

1 (1.5)

Widowed

3 (4.6)

1 (1.5)

Demographics

Income

Over $75,000
Employment

Marital Status

Religion
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5 (7.7)

3 (4.7)

Control (n = 65)

SDP group (n = 65)

n (%)

n (%)

Catholic

8 (12.3)

32 (50)

Protestant Christian

25 (38.5)

9 (14.1)

-

1 (1.6)

22 (33.8)

12 (18.8)

5 (7.7)

7 (10.9)

Demographics

Religion

Muslim
No affiliation
Other
Note. SDP = Smart Device Platform
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Table 4
Health Information Descriptive Statistics by Condition

Medical Information

Control (n = 65)

SDP group (n = 65)

Paroxysmal

26 (54.2)

36 (57.1)

Persistent

12 (25.0)

18 (28.6)

Permanent

7 (14.6)

7 (11.1)

3 (6.3)

2 (3.2)

6 (9.5)

26 (56.3)

Hypertension

39 (60.0)

36 (56.3)

Obesity

26 (41.3)

30 (46.2)

Hyperlipidemia

29 (46.0)

30 (46.2)

1 (1.5)

7 (10.8)

Stroke

8 (12.5)

16 (25.0)

Stent

4 (6.2)

20 (30.8)

CABG

0 (0.0)

15 (23.1)

Balloon Angioplasty

1 (1.5)

15 (24.6)

17 (28.3)

27 (41.5)

ICD

2 (3.2)

21 (32.3)

ILR

5 (7.7)

18 (27.7)

AFib Classification

Unsure
Medical Comorbidities/Procedures
Diabetes

Heart Attack

Cardiac Catheter

Note. CABG = Coronary Artery Bypass Grafting; ICD = Implantable Cardioverter
Defibrillator;
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ILR = Implantable Loop Recorder
Table 5
Means and Standard Deviations of Measures
Control (n = 65)

SDP group (n = 65)

Variable

Mean

SD

Mean

SD

Uncertainty in Illness

82.65

15.00

72.57

12.49

Cardiac Anxiety Total

1.44

0.53

2.26

0.59

Cardiac Fear

1.46

0.55

2.26

0.67

Cardiac Avoidance

1.20

0.80

2.11

0.90

Cardiac Attention

1.63

0.78

2.38

0.56

18.59

7.38

23.20

7.17

AFib Symptoms

15.40

7.28

22.52

8.57

Symptom Burden

16.88

5.89

17.30

4.74

Healthcare Utilization

5.68

1.86

7.78

2.36

-

-

3.66

1.04

Body Vigilance
Atrial Fibrillation Severity Scale

SDP Use

Note. Uncertainty in Illness = MUIS Total Score; Cardiac Anxiety Total = CAQ Total
Score; Cardiac Fear = CAQ-Fear Score; Cardiac Avoidance = CAQ-Avoidance Score;
Cardiac Attention = CAQ-Attention Score; Body Vigilance = BVS Total score; Atrial
Fibrillation Severity Scale = AFSS; AFib Symptoms = AFSS Symptom Score; Symptom
Burden = AFSS Burden Score; Healthcare Utilization = AFSS HCU Score; SDP = Smart
Device Platform
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Figure 1
Cardiac Anxiety across Conditions

Note. Error bars are 95% Confidence Interval.
CAQTOT = Cardiac Anxiety Questionnaire Total Score; CAQ_ATN = Cardiac Anxiety
Questionnaire Attention Score; CAQ_AV = Cardiac Anxiety Questionnaire Avoidance
Score; CAQ_FEAR = Cardiac Anxiety Questionnaire Fear Score; SDP = Smart Device
Platform
n = 65 for each group; N = 130

